237 related articles for article (PubMed ID: 24712857)
1. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
Busch A; Zeh D; Janzen V; Mügge LO; Wolf D; Fingerhut L; Hahn-Ast C; Maurer O; Brossart P; von Lilienfeld-Toal M
Clin Exp Immunol; 2014 Aug; 177(2):439-53. PubMed ID: 24712857
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.
Vo MC; Anh-NguyenThi T; Lee HJ; Nguyen-Pham TN; Jaya Lakshmi T; Jung SH; Kim HJ; Lee JJ
Exp Hematol; 2017 Feb; 46():48-55. PubMed ID: 27889516
[TBL] [Abstract][Full Text] [Related]
3. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Görgün GT; Whitehill G; Anderson JL; Hideshima T; Maguire C; Laubach J; Raje N; Munshi NC; Richardson PG; Anderson KC
Blood; 2013 Apr; 121(15):2975-87. PubMed ID: 23321256
[TBL] [Abstract][Full Text] [Related]
4. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
[TBL] [Abstract][Full Text] [Related]
6. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.
Favaloro J; Liyadipitiya T; Brown R; Yang S; Suen H; Woodland N; Nassif N; Hart D; Fromm P; Weatherburn C; Gibson J; Ho PJ; Joshua D
Leuk Lymphoma; 2014 Dec; 55(12):2893-900. PubMed ID: 24625328
[TBL] [Abstract][Full Text] [Related]
7. CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.
Zhang L; Bi E; Hong S; Qian J; Zheng C; Wang M; Yi Q
Oncotarget; 2015 Nov; 6(34):36032-40. PubMed ID: 26447613
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
Neuber B; Herth I; Tolliver C; Schoenland S; Hegenbart U; Hose D; Witzens-Harig M; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunol; 2011 Jul; 187(2):1047-56. PubMed ID: 21677134
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Scott GB; Carter C; Parrish C; Wood PM; Cook G
Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
[TBL] [Abstract][Full Text] [Related]
11. Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Lee SE; Lim JY; Ryu DB; Kim TW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim M; Min CK
Cancer Immunol Immunother; 2016 Aug; 65(8):983-94. PubMed ID: 27342591
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Kuwahara-Ota S; Shimura Y; Steinebach C; Isa R; Yamaguchi J; Nishiyama D; Fujibayashi Y; Takimoto-Shimomura T; Mizuno Y; Matsumura-Kimoto Y; Tsukamoto T; Chinen Y; Kobayashi T; Horiike S; Taniwaki M; Gütschow M; Kuroda J
Br J Haematol; 2020 Dec; 191(5):784-795. PubMed ID: 32558939
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.
Sakamaki I; Kwak LW; Cha SC; Yi Q; Lerman B; Chen J; Surapaneni S; Bateman S; Qin H
Leukemia; 2014 Feb; 28(2):329-37. PubMed ID: 23765229
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide enhances anti-myeloma cellular immunity.
Luptakova K; Rosenblatt J; Glotzbecker B; Mills H; Stroopinsky D; Kufe T; Vasir B; Arnason J; Tzachanis D; Zwicker JI; Joyce RM; Levine JD; Anderson KC; Kufe D; Avigan D
Cancer Immunol Immunother; 2013 Jan; 62(1):39-49. PubMed ID: 22733396
[TBL] [Abstract][Full Text] [Related]
15. [Immunomodulatory effects of lenalidomide].
Handa H; Saitoh T; Murakami H
Nihon Rinsho; 2015 Jan; 73(1):156-61. PubMed ID: 25626322
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
17. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF;
Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Gandhi AK; Kang J; Capone L; Parton A; Wu L; Zhang LH; Mendy D; Lopez-Girona A; Tran T; Sapinoso L; Fang W; Xu S; Hampton G; Bartlett JB; Schafer P
Curr Cancer Drug Targets; 2010 Mar; 10(2):155-67. PubMed ID: 20088798
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
